Lupin in deal with Abbott and Fournier for Antara; Sun Pharma to sell Merck & Co diabetes drugs
Indian drugmaker Lupin (LOPN: BO) yesterday announced via a filing with the Bombay stock exchange that it has entered into a licensing pact for various patents of the cholesterol lowerer drug Antara (fenofibrate) with US health care major Abbott Laboratories (NYSE: ABT) and French independent drugmaker Laboratoires Fournier SA.
Lupin and its subsidiaries reached agreement for various Antara patents, but declined to disclosed financial terms of the licensing agreement citing confidentiality concerns. The agreement covers as many as eight patents in the US for the drug besides any divisionals, continuations, continuations in part, reissues, re-examinations, and extensions, it added.
MSD in India and Sun Pharma accord for sitagliptin marketing
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze